Аннотация
Clinical studies have been conducted in New Zealand evaluating the safety and immunogenicity of an outer membrane vesicle (OMV) vaccine, MeNZB, developed to control epidemic disease caused by group B meningococci, subtype P1.7b,4. MeNZB, administered in a three-dose regimen, was well tolerated and induced a seroresponse, defined as a four-fold rise (\textgreater or =titre 8) in serum bactericidal antibodies against the vaccine strain 4-6 weeks after the third vaccination, in 96\% (95\% confidence interval (CI): 79-100\%) of adults, 76\% (95\% CI: 72-80\%) of children, 75\% (95\% CI: 69-80\%) of toddlers and 74\% (95\% CI: 67-80\%) of infants receiving MeNZB. In conclusion, these findings suggest that MeNZB is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain.
- adolescent,
- adult,
- aged,
- antibodies,
- b,
- bacterial
- bacterial,
- child,
- female,
- humans,
- infant,
- infections,
- male,
- meningitidis,
- meningococcal
- method,
- middle
- neisseria
- new
- preschool,
- safety
- serogroup
- vaccines,
- zealand,
- {double-blind}
Пользователи данного ресурса
Пожалуйста,
войдите в систему, чтобы принять участие в дискуссии (добавить собственные рецензию, или комментарий)